UCB and Biogen's Phase 3 lupus drug trial shows improved disease activity outcomes, with promising data leading to a second pivotal trial in 2024. Vandana Singh FDA Approves UCB's Psoriasis Drug ...
Barclays analyst Charles Pitman CFA reiterated a Buy rating on UCB SA (0NZT – Research Report) today and set a price target of €240.00. The ...
Barclays analyst Charles Pitman CFA reiterated a Buy rating on UCB SA (0NZT – Research Report) today and set a price target of €240.00. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback